دورية أكاديمية
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
| العنوان: | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. |
|---|---|
| المؤلفون: | Roe, Matthew T., Armstrong, Paul W., Fox, Keith A. A., White, Harvey D., Prabhakaran, Dorairaj, Goodman, Shaun G., Cornel, Jan H., Bhatt, Deepak L., Clemmensen, Peter, Martinez, Felipe, Ardissino, Diego, Nicolau, Jose C., Boden, William E., Gurbel, Paul A., Ruzyllo, Witold, Dalby, Anthony J., McGuire, Darren K., Leiva-Pons, Jose L., Parkhomenko, Alexander, Gottlieb, Shmuel, Topacio, Gracita O., Hamm, Christian, Pavlides, Gregory, Goudev, Assen R., Oto, Ali, Tseng, Chuen-Den, Merkely, Bela, Gasparovic, Vladimir, Corbalan, Ramon, Cinteza, Mircea, McLendon, R. Craig, Winters, Kenneth J., Brown, Eileen B., Lokhnygina, Yuliya, Aylward, Philip E., Huber, Kurt, Hochman, Judith S., Ohman, E. Magnus |
| المساهمون: | LANCELLOTTI, Patrizio |
| المصدر: | New England Journal of Medicine, 367 (14), 1297-309 (2012) |
| بيانات النشر: | Massachusetts Medical Society, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Acute Coronary Syndrome/drug therapy, Aged, Angina, Unstable/drug therapy, Aspirin/therapeutic use, Cardiovascular Diseases/mortality/prevention & control, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction/drug therapy/epidemiology, Piperazines/adverse effects/therapeutic use, Platelet Aggregation Inhibitors/adverse effects/therapeutic use, Purinergic P2 Receptor Antagonists/adverse effects/therapeutic use, Stroke/epidemiology, Thiophenes/adverse effects/therapeutic use, Ticlopidine/adverse effects/analogs & derivatives/therapeutic use, Human health sciences, Cardiovascular & respiratory systems, Sciences de la santé humaine, Systèmes cardiovasculaire & respiratoire |
| الوصف: | BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. RESULTS: At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article |
| اللغة: | English |
| العلاقة: | urn:issn:0028-4793; urn:issn:1533-4406 |
| DOI: | 10.1056/NEJMoa1205512 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/151550Test |
| حقوق: | restricted access http://purl.org/coar/access_right/c_16ecTest info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsorb.151550 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1056/NEJMoa1205512 |
|---|